Want to see TSE:ASG full AI Analyst Report?
ASG Stock Chart & Stats
C$0.19
C$0.01(4.88%)
At close: 4:00 PM EDT
C$0.19
C$0.01(4.88%)
Day’s Range― - ―
52-Week RangeC$0.13 - C$0.33
Previous CloseN/A
Volume127.00
Average Volume (3M)17.77K
Market Cap
C$10.15M
Enterprise ValueC$21.95
Total Cash (Recent Filing)C$362.04K
Total Debt (Recent Filing)C$2.17M
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Nov 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding78,092,200
10 Day Avg. Volume7,907
30 Day Avg. Volume17,772
Financial Highlights & Ratios
PEG Ratio0.79
Price to Book (P/B)4.02
Price to Sales (P/S)0.83
P/FCF Ratio36.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Revenue Scale And Operating LeverageRevenue remains materially above earlier years, while slightly positive EBITDA in 2025 and 2026 TTM indicates emerging operating leverage. If maintained, this combination could improve the earnings base and support a more scalable medical-device business over the next several quarters.
Positive Operating And Free Cash FlowPositive operating and free cash flow since 2024 is a meaningful improvement from 2021–2023 and shows that cash generation has outpaced reported earnings. This provides liquidity support and may reduce reliance on external funding if the improvement proves durable.
Improving LeverageThe lower debt-to-equity ratio indicates improving leverage and reduces balance-sheet pressure relative to the prior annual period. A more moderate capital structure can preserve financial flexibility for operations and investment while limiting the burden of debt on future cash flows.
Bears Say
Persistent Losses And Declining Equity CushionPersistent losses continue to erode shareholders’ equity, leaving a shrinking cushion against operating setbacks. Although leverage is improving, ongoing negative returns on equity indicate that the business has not yet established durable profitability or consistently created value from its capital base.
Recent Revenue ContractionThe latest revenue decline shows that earlier expansion has not yet translated into consistent forward momentum. Continued contraction could limit operating leverage, weaken the path to sustainable profitability, and make it harder for Aurora Spine to convert its larger revenue base into dependable earnings.
Free Cash Flow VolatilityThe sharp latest decline in free cash flow makes the recent cash-generation improvement less proven and suggests that working-capital movements or reinvestment needs may be affecting results. If sustained, weaker cash conversion could constrain liquidity and reduce funding flexibility.
Aurora Spine News
ASG FAQ
What was Aurora Spine Corp’s price range in the past 12 months?
Aurora Spine Corp lowest stock price was C$0.13 and its highest was C$0.33 in the past 12 months.
What is Aurora Spine Corp’s market cap?
Aurora Spine Corp’s market cap is C$10.15M.
When is Aurora Spine Corp’s upcoming earnings report date?
Aurora Spine Corp’s upcoming earnings report date is Nov 17, 2026 which is in 54 days.
How were Aurora Spine Corp’s earnings last quarter?
Aurora Spine Corp released its earnings results on Aug 27, 2026. The company reported -C$0.015 earnings per share for the quarter.
Is Aurora Spine Corp overvalued?
According to Wall Street analysts Aurora Spine Corp’s price is currently Overvalued.
Does Aurora Spine Corp pay dividends?
Aurora Spine Corp does not currently pay dividends.
What is Aurora Spine Corp’s EPS estimate?
Aurora Spine Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aurora Spine Corp have?
Aurora Spine Corp has 78,092,200 shares outstanding.
What happened to Aurora Spine Corp’s price movement after its last earnings report?
Aurora Spine Corp reported an EPS of -C$0.015 in its last earnings report. Following the earnings report the stock price went down -9.756%.
Which hedge fund is a major shareholder of Aurora Spine Corp?
Currently, no hedge funds are holding shares in TSE:ASG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aurora Spine Corp
Established in 2013 and headquartered in Toronto, Canada, Aurora Spine Corporation, through its subsidiary Aurora Spine, Inc., specializes in the development and distribution of advanced, minimally invasive spinal fusion systems and devices within the Canadian market. The company offers a comprehensive portfolio of products designed to address various spinal conditions, particularly degenerative disc diseases. This includes interspinous process lumbar fusion devices such as the ZIP series (ZIP, ZIP ULTRA, ZIP LP, and ZIP-51). Aurora Spine also provides Ti-Coated polyether ether ketone (PEEK) interbody cages, which are crucial for maintaining space and stability between vertebrae while facilitating bone fusion. Its offerings extend to sterile-packed titanium plasma spray coated spinal fusion implants that promote bone growth. Key interbody products comprise EOS, VOX, Echo, Echo SD, and EchoXL for the lumbar region, and Discovery for cervical applications. The company also manufactures SOLO, an anterior lumbar interbody fusion (ALIF) 3D-printed stand-alone device featuring an integrated plate and spacer system for anatomical preservation and spinal support. For sacroiliac joint issues, Aurora Spine provides SiLo, a posterior fusion device. Furthermore, the DEXA-C cervical interbody system, a porous 3D-printed intervertebral body fusion device with customizable lattice density options, is available to match patient bone quality.
Technical Analysis
Perimeter Medical Imaging AI
―
―
Theralase Technologies
―
VentriPoint Diagnostics
―
―